Data-analysis methods and variability of patient response figured into the second-half phase II surprise for Ohr Pharmaceutical Inc. with its eye-drop combination therapy for wet age-related macular degeneration (AMD), but the company said lessons from the study – results of which are still being sorted – will optimize the phase III program, due to start a few months later than originally planned.